课题基金 / 基金详情

项目摘要

项目成果

JOHN S. LAZO的其他基金

相似基金

相关文献

中文摘要
翻译
电离辐射诱导细胞中的RNA,其可以在辐射之前被siRNA靶向以鉴定新的RNA。 辐射防护药物的靶点。我们已经成功地用这种策略来鉴定一种常见的药物, 新型抗辐射剂格列本脲。我们现在建议应用这一策略来识别辐射缓解剂 使用放射敏感的人细胞靶点和照射后siRNA筛选的药物。1** 具体目标将 优化和部署前哨细胞,用于检测新缓解药物的RNA靶点。第二个目标是 使用可药物化的siRNA文库和小分子文库来鉴定辐射损伤缓解剂。的 第三个目标是确定与优先药物积极相互作用的靶点,以促进辐射缓解 方面的影响.
英文摘要
Ionizing irradiation induces RNAs in cells which can be targeted prior to irradiation by siRNA to identify novel targets for radioprotector drugs. We have successfully used this strategy to identify a co,mmon drug, Glyburide, as a novel radioprotector. We now propose to apply this strategy to identify radiation mitigator drugs using radiosensitive human cell targets and siRNA screening after irradiation. The 1** Specific Aim will optimize and deploy sentinel cells for detecting RNA targets for new mitigator drugs. The second aim will be to use druggable siRNA libraries and small molecule libraries to identify radiation damage mitigators. The third aim will be to identify targets that interact positively with prioritized drugs to advance radiation mitigation effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury
  • 批准号:
    10632154
  • 项目类别:
  • 资助金额:
    $0.65万
  • 财政年份:
    2022
  • 负责人:
    JOHN S. LAZO
  • 依托单位:
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury
  • 批准号:
    10330408
  • 项目类别:
  • 资助金额:
    $25.22万
  • 财政年份:
    2021
  • 负责人:
    JOHN S. LAZO
  • 依托单位:
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury
  • 批准号:
    10540550
  • 项目类别:
  • 资助金额:
    $5.5万
  • 财政年份:
    2021
  • 负责人:
    JOHN S. LAZO
  • 依托单位:
Developing small molecule PTP4A3 inhibitors for ovarian cancer
  • 批准号:
    9769367
  • 项目类别:
  • 资助金额:
    $28.93万
  • 财政年份:
    2019
  • 负责人:
    JOHN S. LAZO
  • 依托单位:
海外基金